ARTICLE | Company News
Almirall Prodesfarma S.A., Forest Laboratories deal
April 17, 2006 7:00 AM UTC
Almirall granted FRX U.S. rights to LAS34273, an inhalable long-acting muscarinic receptor antagonist that has completed Phase II testing for chronic obstructive pulmonary disease (COPD). Phase III ...